A detailed history of Capital International Sarl transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Capital International Sarl holds 117,025 shares of BMY stock, worth $6.53 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
117,025
Previous 56,137 108.46%
Holding current value
$6.53 Million
Previous $2.33 Million 159.8%
% of portfolio
0.16%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $2.41 Million - $3.15 Million
60,888 Added 108.46%
117,025 $6.06 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $13.6 Million - $17.8 Million
-336,680 Reduced 85.71%
56,137 $2.33 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $2.15 Million - $2.44 Million
44,767 Added 12.86%
392,817 $21.3 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $1.03 Million - $1.23 Million
21,296 Added 6.52%
348,050 $17.9 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $1.93 Million - $2.15 Million
-33,277 Reduced 9.24%
326,754 $19 Million
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $4.48 Million - $4.98 Million
70,357 Added 24.29%
360,031 $23 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $11.2 Million - $12.7 Million
170,811 Added 143.7%
289,674 $20.1 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $1.14 Million - $1.35 Million
16,611 Added 16.25%
118,863 $8.55 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $7,171 - $4.24 Million
55,163 Added 117.15%
102,252 $7.27 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $1.91 Million - $2.1 Million
-26,304 Reduced 35.84%
47,089 $3.63 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $4.51 Million - $5.41 Million
73,393 New
73,393 $5.36 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $119B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Capital International Sarl Portfolio

Follow Capital International Sarl and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Sarl with notifications on news.